MX2024002112A - Anticuerpos anti-vegfr1 y sus usos. - Google Patents

Anticuerpos anti-vegfr1 y sus usos.

Info

Publication number
MX2024002112A
MX2024002112A MX2024002112A MX2024002112A MX2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A
Authority
MX
Mexico
Prior art keywords
vegfr1
antibodies
vegfr1 antibodies
polynucleotides
vectors
Prior art date
Application number
MX2024002112A
Other languages
English (en)
Spanish (es)
Inventor
Songmao Zheng
Ronald V Swanson
Thomas J Rutkoski
Matthew D Breyer
Villalobos Romer A Gonzalez
Jingjun Li
Gang Zheng
Xirong Zheng
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2024002112A publication Critical patent/MX2024002112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002112A 2021-08-16 2022-08-12 Anticuerpos anti-vegfr1 y sus usos. MX2024002112A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233343P 2021-08-16 2021-08-16
US202263322273P 2022-03-22 2022-03-22
PCT/US2022/074891 WO2023023465A1 (en) 2021-08-16 2022-08-12 Anti-vegfr1 antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2024002112A true MX2024002112A (es) 2024-05-03

Family

ID=85239767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002112A MX2024002112A (es) 2021-08-16 2022-08-12 Anticuerpos anti-vegfr1 y sus usos.

Country Status (14)

Country Link
US (1) US20240425603A1 (cg-RX-API-DMAC7.html)
EP (1) EP4388011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534034A (cg-RX-API-DMAC7.html)
KR (1) KR20240046239A (cg-RX-API-DMAC7.html)
CN (1) CN119285771A (cg-RX-API-DMAC7.html)
AU (1) AU2022331414A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229430A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000445A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001686A2 (cg-RX-API-DMAC7.html)
IL (1) IL310840A (cg-RX-API-DMAC7.html)
MX (1) MX2024002112A (cg-RX-API-DMAC7.html)
TW (1) TW202315888A (cg-RX-API-DMAC7.html)
UY (1) UY39900A (cg-RX-API-DMAC7.html)
WO (1) WO2023023465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260051101A (ko) * 2023-04-26 2026-04-15 사이즈믹 테라퓨틱, 인코포레이티드. 면역 체계를 조절하는 분자 및 그 용도
WO2026072909A2 (en) * 2024-09-27 2026-04-02 Amgen Inc. Flt1 binding proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013176366A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Vegfr1由来ペプチドおよびそれを含むワクチン
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
TW201517916A (zh) * 2013-03-15 2015-05-16 Lilly Co Eli Vegfr1抗體之治療用途
US10738123B2 (en) * 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Also Published As

Publication number Publication date
WO2023023465A1 (en) 2023-02-23
KR20240046239A (ko) 2024-04-08
AU2022331414A1 (en) 2024-04-04
JP2024534034A (ja) 2024-09-18
CO2024001686A2 (es) 2024-02-26
US20240425603A1 (en) 2024-12-26
CL2024000445A1 (es) 2024-08-23
EP4388011A4 (en) 2025-07-30
EP4388011A1 (en) 2024-06-26
TW202315888A (zh) 2023-04-16
CN119285771A (zh) 2025-01-10
UY39900A (es) 2023-02-28
CA3229430A1 (en) 2023-02-23
IL310840A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
EA202091859A1 (ru) Применение антител к sirpa v1 человека и способ получения антител к sirpa v1
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MX2021004775A (es) Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2024002476A (es) Anticuerpos anti-psma y usos de estos.
MX2022015203A (es) Moleculas de union al dominio fc de activacion inmunitaria.
PH12019500600A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
EA201990578A1 (ru) Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
EP4464333A3 (en) Anti-death receptor antibodies and methods of use thereof
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
CO2024001686A2 (es) Anticuerpos anti-vegfr1 y sus usos
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2024002479A (es) Radioconjugados anti-psma y usos de estos.
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
EP4570824A3 (en) Pd1 and vegfr2 dual-binding agents